Suvretta Capital Management

Suvretta Capital Management is an investment management firm with multiple long/short equity strategies, including two focused on the healthcare and biopharmaceutical sectors. It invests in public companies developing innovative therapies but does not conduct clinical trials or have its own drug pipeline[1][6].

Its Averill Partners fund has been one of the top-performing biopharma-focused hedge funds since launch in 2020, compounding at over 385% net of fees through late 2024. The fund specializes in identifying companies with disruptive approaches to disease treatment and has significant holdings in small-to-mid cap biotech firms[6].

The newer Averill Madison fund focuses on mid-to-large cap health care companies and also delivered strong returns since inception[6].